Aarti Drugs Limited

NSEI:AARTIDRUGS Rapporto sulle azioni

Cap. di mercato: ₹44.8b

Aarti Drugs Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Aarti Drugs ha un patrimonio netto totale di ₹12.8B e un debito totale di ₹5.9B, che porta il suo rapporto debito/patrimonio netto a 46%. Le sue attività totali e le sue passività totali sono rispettivamente ₹24.3B e ₹11.5B. L'EBIT di Aarti Drugs è ₹2.4B rendendo il suo rapporto di copertura degli interessi 7.4. Ha liquidità e investimenti a breve termine pari a ₹295.6M.

Informazioni chiave

46.0%

Rapporto debito/patrimonio netto

₹5.88b

Debito

Indice di copertura degli interessi7.4x
Contanti₹295.60m
Patrimonio netto₹12.78b
Totale passività₹11.52b
Totale attività₹24.30b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Sep 20
We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Sep 05
Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

May 04
Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Feb 01
Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Jan 30
Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

May 17
Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

Nov 22
These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet

Aug 28
We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet

Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching

Aug 19
Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching

Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value

May 17
Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value

Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock

Apr 04
Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock

Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?

Mar 17
Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Mar 02
Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?

Feb 17
What Percentage Of Aarti Drugs Limited (NSE:AARTIDRUGS) Shares Do Insiders Own?

Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio

Feb 04
Why Aarti Drugs Limited (NSE:AARTIDRUGS) Should Be In Your Dividend Portfolio

What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?

Jan 22
What Can We Learn About Aarti Drugs' (NSE:AARTIDRUGS) CEO Compensation?

Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth

Jan 07
Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth

If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late

Dec 23
If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late

Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly

Dec 08
Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Nov 23
Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?

Nov 08
How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?

Here's What We Learned About The CEO Pay At Aarti Drugs Limited (NSE:AARTIDRUGS)

Oct 11
Here's What We Learned About The CEO Pay At Aarti Drugs Limited (NSE:AARTIDRUGS)

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ₹12.6B ) di AARTIDRUGS superano le sue passività a breve termine ( ₹7.8B ).

Passività a lungo termine: Le attività a breve termine di AARTIDRUGS ( ₹12.6B ) superano le sue passività a lungo termine ( ₹3.7B ).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 43.7% ) di AARTIDRUGS è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di AARTIDRUGS si è ridotto da 77% a 46% negli ultimi 5 anni.

Copertura del debito: Il debito di AARTIDRUGS è ben coperto dal flusso di cassa operativo ( 52.4% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di AARTIDRUGS sono ben coperti dall'EBIT ( 7.4 x copertura).


Bilancio


Scoprire le aziende sane